You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
先聲藥業(02096.HK)初段跌7.6% 研發新冠藥或被輝瑞Paxlovid「截胡」
阿思達克 01-10 09:46
輝瑞(PFE.US)稱正為新冠口服抗病毒藥物Paxlovid上半年在中國銷售作準備,研發新冠藥的先聲藥業(02096.HK)今日(10日)輕微低開0.3%,報12.66元後,初段跌幅急擴,最低見11.5元。現報11.74元,跌7.56%,成交7,556.37萬股,涉資8.84億元。 先聲藥業(02096.HK)市前錄6,470萬股U盤成交,每股作價11.684元,涉款約7.56億元。 該股昨日(9日)升5.8%,據國家醫療保障局消息,2022年國家醫保藥品目錄談判工作結束,Paxlovid未能入選。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account